Effect of valproic acid on perampanel pharmacokinetics in patients with epilepsy

Manuela Contin, Francesca Bisulli, Margherita Santucci, Roberto Riva, Francesca Tonon, Susan Mohamed, Lorenzo Ferri, Carlotta Stipa, Paolo Tinuper

Epilepsia · 2018 · 29 citations · 13 references

DOIFull text

Open access

Concepts

Abstract

Summary We prospectively examined the effect of antiepileptic ( AED ) cotherapy on steady state plasma concentrations of perampanel ( PMP ) in epileptic patients. We classified AED s as strong enzyme inducers (carbamazepine, phenobarbital, phenytoin, oxcarbazepine), not strong enzyme inducers/not inhibitors (levetiracetam, lamotrigine, topiramate, rufinamide, lacosamide, zonisamide, clobazam), and enzyme inhibitors (valproic acid [ VPA ]). The main outcome was the comparison of PMP plasma concentration to weight‐adjusted dose ratio (C/D; [μg/mL]/mg kg −1 d −1 ) among comedication subgroups. From 79 patients (42 females, 37 males) aged (mean ± standard deviation) 33 ± 13 years (range = 12‐66 years), 114 plasma samples were collected. Twenty‐eight patients (44 samples) were cotreated with enzyme inducers (group A), 21 (27 samples) with not strong enzyme inducers/not inhibitors (group B), 21 (31 samples) with not strong enzyme inducers/not inhibitors + VPA (group C), and 9 (12 samples) with enzyme inducers + VPA (group D). PMP C/D was reduced (−56%, P < .001) in group A (1.79 ± 0.80) versus group B (4.05 ± 2.16) and increased ( P < .001) in group C (6.72 ± 4.04) compared with groups A (+275%), B (+66%), and D (2.76 ± 2.00, +143%). Our study documents the unpublished higher PMP C/D in patients cotreated with VPA . These findings have both theoretical relevance, suggesting better characterization of PMP metabolic pathways with ad hoc studies, and clinical usefulness in managing patients on AED polytherapy.

References

13